This platform provides excellent new opportunities for translational research in AML 🚀.

Don’t hesitate to contact us if you are interested in *PDX AML models.

Many thanks to all collaborators and co-authors who made this work possible!

#Leukemia #AML #PDX #TranslationalResearch #Preprint

In one year-long in vivo trials mimicking clinical chemotherapy, we observed a surprising pattern:

📉 leukemia growth gradually declined after each treatment block

These *PDX models allow:
🔄 serial transplantation
🧬 genetic engineering
🐁 functional and molecular studies, both in vivo and ex vivo
🧪 faithful representation of primary AML biology – beyond what cell lines can deliver.

We present robust AML PDX models (*PDX) covering subgroups where no cell lines exist – opening new doors for ex vivo and in vivo studies.

🚨 New preprint alert! 🚨

We just posted our latest manuscript on patient-derived xenograft (PDX) models in acute myeloid leukemia (AML):

📝 "A platform of robust patient-derived leukemia models covering subgroups for which no cell lines exist"

www.biorxiv.org/content/10.1...

Why this matters ⬇️

These *PDX models allow:

🔄 serial transplantation
🧬 genetic engineering
🐁 functional and molecular studies, both in vivo and ex vivo
🧪 faithful representation of primary AML biology – beyond what cell lines can deliver.

We present robust AML PDX models (*PDX) covering subgroups where no cell lines exist – opening new doors for ex vivo and in vivo studies.

P27 @sercoz.bsky.social
In vivo CRISPR-Cas9 screening in PDX models reveals CCND3 as a new therapeutic vulnerability

P39 @binjev.bsky.social
Serially transplantable PDX models for AML subtypes for which no cell lines exist

If you’re attending, don’t miss our posters! We’ll be sharing our latest research using genetically engineered Acute Leukemia PDX models—and we’d love to connect with you.

P18 @kkuhbandner.bsky.social
A novel Decitabine analogue with enhanced anti-leukemia activity and reduced toxicity in vivo

🚀 The 12th International Heidelberg Symposium on Stem Cells and Cancer – SCC2025 kicks off today!

The @jeremiaslab.bsky.social is thrilled to join leading experts to explore groundbreaking advances in the cancer stem cell field and spark new discussions.

stem-cells-cancer.de/event/scc2025/

Our recent lab trip to Oberammergau was the perfect mix of adventure, fresh mountain air, and team spirit 🌲💧. Exploring together and sharing new experiences outside the lab made this a truly memorable summer day! #acute#leukemia#research

Many thanks to Jan-Henning Klusmann, Olaf Heidenreich, @rolfmarschalek.bsky.social and Martin Stanulla for the organization!

See you there 😀!

🔬 @jeremiaslab.bsky.social is excited to attend the XXXVI. Kind-Philipp-Meeting! Irmela, @sercoz.bsky.social and Dhruv Mehra are on their way to Wilsede.

www.kind-philipp-meeting.de

Looking forward to an engaging program and to meeting experts and early career researchers in paediatric cancer!

Visit our poster “A CRISPR/Cas9 pipeline to uncover potential therapeutic targets in PDX models of acute lymphoblastic leukemia" and learn more about our work.

Looking forward to connecting with fellow researchers in the ALL field. See you there!

📢 We’re heading to Dublin!

Irmela Jeremias will be attending the 4th Translational Research Conference: Acute Lymphoblastic Leukaemia (ALL).

We’re excited to share our latest research during the poster session.

#ESHALL2025 #LeukemiaResearch #CRISPR #PDXmodels #TranslationalResearch

A PhD position is open in my group here in Heidelberg. We'll use cool primary cell models of osteosarcoma and genetic screens to understand and overcome mechanisms of clinically acquired drug resistance. It'll be a blast!

karriere.klinikum.uni-heidelberg.de/index.php?ac...

Looking forward to connecting with fellow pediatricians and presenting our latest findings on patient-derived xenograft models for AML.

🗣️ Don't miss Irmela‘s talk about "Serially transplantable PDX models for AML subtypes for which no cell lines exist“

🔬 Excited to share that Irmela Jeremias will be attending the 14th I-BFM Biennial Childhood Leukemia and Lymphoma Symposium this weekend in Budapest!

clls-symposium.org

🌸Science in full blossom 🌸

Last week the @jeremiaslab.bsky.social had a productive get-together culminating in fresh ideas, collaborative energy, team spirit and a picture under the beautiful cherry blossoms. Nothing like spring to inspire new discoveries! #Science#AcuteLeukemia

Great and incredibly important initiative! Thank you for organizing this event!

🎉 We’re excited to share our latest research on FLT3-targeted antibody-drug conjugates (ADCs) as a promising strategy to eliminate leukemic stem cells in AML! 🚀🔬Many thanks to all involved in this great BMBF-funded project #leukemia #PDXmodels

📖Read more here: www.nature.com/articles/s41...

We wrapped up an amazing and successful year in the
@jeremiaslab.bsky.social with a wonderful party, delicious food, and great company. Wishing everyone a joyful holiday season and a fantastic start to 2025! 🎉🍽️✨